INTRODUCTIONrnThe adult human skeleton is a dynamic organ that undergoes continuous remodeling throughout life to support whole-body mineral homeostasis while sustaining structural integrity. Healthy remodeling requires the balancing activities of bone resorption by osteoclasts and bone formation by osteoblasts.1 Loss of the balance in favor of bone resorption causes a net bone loss, resulting in osteopenia or in the more severe cases osteoporosis, a hallmark of aging. The current therapeutics for osteoporosis include two bone anabolic agents, namely teriparatide and abaloparatide, both recombinant proteins that activate the parathyroid hormone receptor PTH1R.2 However, the clinical use of those drugs is limited due to unresolved concs about osteosarcoma.3 Thus, additional bone anabolic therapies are necessary to fulfill the unmet needs among osteoporotic patients. Such new therapies are also needed to promote bone fracture healing which is often negatively impacted by aging and diabetes.4-5